



TO MAGNIFICO RETTORE OF UNIVERSITA' DEGLI STUDI DI MILANO

ID CODE: 4411

I the undersigned asks to participate in the public selection, for qualifications and examinations, for the awarding of a type B fellowship at **Dipartimento di Fisiopatologia Medico-Chirurgica e dei Trapianti**

Scientist- in - charge: Prof. Payvandi

[Shermarke Hassan]

## CURRICULUM VITAE

### PERSONAL INFORMATION

Surname	Hassan
Name	Shermarke
Date of birth	[03, 07, 1989]

### PRESENT OCCUPATION

Appointment	Structure
PhD student Clinical Epidemiology	?

### EDUCATION AND TRAINING

Degree	Course of studies	University	year of achievement of the degree
Degree	BSc Medicine	University of Maastricht	2013
Specialization	MSc Epidemiology	University of Maastricht	2015
PhD	PhD Clinical Epidemiology	Leiden University	Expected date (2020)
Master			
Degree of medical specialization			
Degree of European specialization			
Other			



## REGISTRATION IN PROFESSIONAL ASSOCIATIONS

Date of registration	Association	City
-	-	-

## FOREIGN LANGUAGES

Languages	level of knowledge
Dutch	Native speaker
Somali	Native speaker
English	Fluent
German	Good working knowledge

## AWARDS, ACKNOWLEDGEMENTS, SCHOLARSHIPS

Year	Description of award
EAHAD travel grant	Based on the content of an abstract, a travel grant was awarded (1500 EUR) for the EAHAD 2019 congress in Prague
Leiden University Fund	A grant (1875 EUR) was awarded by the Leiden University Fund for a three month stay as a visiting researcher in Milan from 14-01-2019 to 14-04-2019

## TRAINING OR RESEARCH ACTIVITY

<p>PhD in clinical Epidemiology at Leiden University Medical Centre, activities:</p> <ul style="list-style-type: none"><li>• Setting up a multi-centre clinical trial in 9 hospitals</li><li>• Writing the study protocol</li><li>• Obtaining medical-ethical approval for the study</li><li>• Obtaining informed consent from patients, collection of study samples and data</li><li>• Communication with laboratories and local researchers</li><li>• Data analysis</li><li>• Writing and publishing peer-reviewed scientific articles that focus on mainly on epidemiology and immunology.</li><li>• Teaching at the faculty of medicine and biomedical sciences.</li><li>• Supervising other members of the project team (data manager, research nurse, students)</li></ul>
<p>Relevant courses:</p> <ul style="list-style-type: none"><li>• Basic course on Regulations and Organisation for clinical investigators (ICH-GCP certification)</li><li>• Basic methods and reasoning in Biostatistics</li><li>• Course on Clinical Epidemiology (Schiermonnikoog course)</li><li>• Course on Principles, Methods, and Applications for Clinical Research (Grobbee)</li><li>• Course on Causal Inference (Hernan)</li><li>• Course on Advanced Epidemiological Methods</li></ul>



## PROJECT ACTIVITY (OTHER THAN PHD)

Year	Project
2017-2019	Coordinator of a Dutch nationwide biobank for patients with haemophilia.  <i>Key responsibilities:</i> <ul style="list-style-type: none"><li>• Obtaining the cooperation of all Dutch academic centres for this project</li><li>• Coordinating the set-up of the local laboratories and IT infrastructure</li><li>• Obtaining medical-ethical approval</li><li>• Coordinating samples and data collection</li><li>• Supervising the first use cases of the biobank for clinical research</li></ul>
2014-2015	Master thesis epidemiology at Maastricht University: “smoking, oestrogen-positive breast cancer and effect modification by genotype”.

## PATENTS

Patent
-
-

## CONGRESSES AND SEMINARS (ORAL PRESENTATIONS)

Date	Title	Place
15-09-2017	“Factor VIII products and inhibitor development in previously treated patients with severe haemophilia A: a systematic review and meta-analysis”	2nd international conference on inhibitors in haemophilia in Milan
08-02-2019	“Mortality of patients with hemophilia in the Netherlands, 2001-2018”	European Association for Haemophilia and Allied Disorders (EAHAD) congress in Prague
06-09-2019	“Performance of a clinical risk prediction model for inhibitor formation in severe hemophilia A”	10th BIC conference in Genoa

## PUBLICATIONS

Published
A. Donners, S. Hassan, K. Rademaker, C. Smit. Antistofvorming kan medicijn hinderen in werkzaamheid. Pharmaceutisch weekblad 2017;152(35):16-18
S. Hassan, A. Cannavò, S.C. Gouw, F.R. Rosendaal, J.G. van der Bom. Factor VIII products and inhibitor development in previously treated patients with severe or moderately severe hemophilia A: a systematic review. J Thromb Haemost 2018;16(6):1055-1068.
S. Hassan, C.J. Fijnvandraat, J.G. van der Bom, S.C. Gouw. Preventing or eradicating factor VIII antibody formation in patients with hemophilia A; what can we learn from other disorders? Seminars of thrombosis and hemostasis. 2018 Sep;44(6):531-543



Articles under review

Shermarke Hassan, Rory C. Monahan, Evelien P. Mauser-Bunschoten, Lize F.D. van Vulpen, Jeroen Eikenboom, Erik A.M. Beckers, Louise Hooimeijer, Paula F. Ypma, Laurens Nieuwenhuizen, Michiel Coppens, Saskia E.M. Schols, Frank W.G. Leebeek, Cees Smit, Mariëtte H. Driessens, S. le Cessie, E.C. van Balen, Frits R. Rosendaal, Johanna G. van der Bom, Samantha C. Gouw. Mortality, life expectancy and causes of death of persons with hemophilia in the Netherlands 2001-2018.

Congress proceedings (not already published or under review)

S. Hassan, R. Palla, C. Valsecchi, I. Garagiola, A. El-Beshlawy, M. Elalfy, V. Ramanan, P. Eshghi, S.C. Gouw, P.M. Mannucci, F.R. Rosendaal, F. Peyvandi. Performance of a clinical risk prediction model for inhibitor formation in severe hemophilia A. [abstract]. In: Proceedings of the 10th BIC conference; 2019 Sep 6-9; Genua, Italy: Haematologica; 2019. Abstract nr P0-02.

OTHER INFORMATION

-
-

Declarations given in the present curriculum must be considered released according to art. 46 and 47 of DPR n. 445/2000.

The present curriculum does not contain confidential and legal information according to art. 4, paragraph 1, points d) and e) of D.Lgs. 30.06.2003 n. 196.

Place and date: Leiden, 26-11-2019

SIGNATURE